The Experts below are selected from a list of 50934 Experts worldwide ranked by ideXlab platform
Joann E Manson - One of the best experts on this subject based on the ideXlab platform.
-
abstract 73 Sex Hormone binding globulin a novel hormonal biomarker for ischemic stroke risk
Stroke, 2020Co-Authors: Tracy E Madsen, Joann E Manson, Xi Luo, Mengna Huang, Ki Park, Marcia L Stefanick, Simin LiuAbstract:Introduction: Sex Hormone binding globulin (SHBG) is a Sex-steroid transporter previously linked to cardiometabolic outcomes such as diabetes (DM) and coronary heart disease and their risk factors....
-
circulating shbg Sex Hormone binding globulin and risk of ischemic stroke findings from the whi
Stroke, 2020Co-Authors: Tracy E Madsen, Mengna Huang, Ki Park, Marcia L Stefanick, Joann E MansonAbstract:Background and Purpose— Circulating levels of SHBG (Sex Hormone-binding globulin) have been inversely linked to obesity, diabetes mellitus, and other cardiometabolic disorders. It remains uncertain...
-
abstract p047 circulating testosterone and Sex Hormone binding globulin concentrations and risk of type 2 diabetes cardiovascular disease and all cause mortality in us women
Circulation, 2019Co-Authors: Tianyi Huang, Joann E Manson, Kathryn M Rexrode, Susan E Hankinson, Shelley S TworogerAbstract:Introduction: It remains unclear whether circulating testosterone and Sex Hormone-binding globulin (SHBG) are associated with cardiometabolic disease risk and mortality. Hypothesis: Higher SHBG and...
-
Sex Hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal Hormone therapy effects
Breast Cancer Research, 2014Co-Authors: Shanshan Zhao, Joann E Manson, Rowan T Chlebowski, Garnet L Anderson, Lewis H Kuller, Margery Gass, Ruth E Patterson, Thomas E Rohan, Dorothy S Lane, Shirley A A BeresfordAbstract:Introduction: Paradoxically, a breast cancer risk reduction with conjugated equine estrogens (CEE) and a risk elevation with CEE plus medroxyprogesterone acetate (CEE + MPA) were observed in the Women’s Health Initiative (WHI) randomized controlled trials. The effects of Hormone therapy on serum Sex Hormone levels, and on the association between baseline Sex Hormones and disease risk, may help explain these divergent breast cancer findings. Methods: Serum Sex Hormone concentrations were measured for 348 breast cancer cases in the CEE + MPA trial and for 235 cases in the CEE trial along with corresponding pair-matched controls, nested within the WHI trials of healthy postmenopausal women. Association and mediation analyses, to examine the extent to which Sex Hormone levels and changes can explain the breast cancer findings, were conducted using logistic regression. Results: Following CEE treatment, breast cancer risk was associated with higher concentrations of baseline serum estrogens, and with lower concentrations of Sex Hormone binding globulin. However, following CEE + MPA, there was no association of breast cancer risk with baseline Sex Hormone levels. The Sex Hormone changes from baseline to year 1 provided an explanation for much of the reduced breast cancer risk with CEE. Specifically, the treatment odds ratio (95% confidence interval) increased from 0.71 (0.43, 1.15) to 0.92 (0.41, 2.09) when the year 1 measures were included in the logistic regression analysis. In comparison, the CEE + MPA odds ratio was essentially unchanged when these year 1 measures were included. Conclusions: Breast cancer risk remains low following CEE use among women having favorable baseline Sex Hormone profiles, but CEE + MPA evidently produces a breast cancer risk for all women similar to that for women having an unfavorable baseline Sex Hormone profile. These patterns could reflect breast ductal epithelial cell stimulation by CEE + MPA that is substantially avoided with CEE, in conjunction with relatively more favorable effects of either regimen following a sustained period of estrogen deprivation. These findings may have implications for other Hormone therapy formulations and routes of delivery.
-
Sex Hormone levels and risk of breast cancer with estrogen plus progestin
Journal of the National Cancer Institute, 2013Co-Authors: Ghada N Farhat, Joann E Manson, Rowan T Chlebowski, Garnet L Anderson, Neeta Parimi, Alison J Huang, Eric Vittinghoff, Jennifer Lee, Andrea Z Lacroix, Jane A CauleyAbstract:Methods We conducted a nested case–control study within the Women’s Health Initiative randomized clinical trial of E+P. The trial enrolled 16 608 postmenopausal women aged 50 to 79 years with intact uterus and no breast cancer history. During a mean of 5.6 years of follow-up, 348 incident breast cancer case subjects were identified and matched with 348 control subjects. Case and control subjects had their Sex Hormone levels measured at baseline (estrogens, testosterone, progesterone, and Sex Hormone–binding globulin [SHBG]) and year 1 (estrogens and SHBG) using sensitive assays. All statistical tests were two-sided. Results Statistically significant elevations in breast cancer risk were seen with greater pretreatment levels of total estradiol (Ptrend = .04), bioavailable estradiol (Ptrend = .03), estrone (Ptrend = .007), and estrone sulfate (Ptrend = .007). E+P increased all measured estrogens and SHGB at year 1 (all P < .001). The effect of E+P on breast cancer risk was strongest in women whose pretreatment levels of total estradiol, bioavailable estradiol, and estrone were in the lowest quartiles. For example, the odds ratio for E+P relative to placebo was 2.47 (95% confidence interval [CI] = 1.28 to 4.79) in the lowest total estradiol quartile, compared with 0.96 (95% CI = 0.44 to 2.09) in the highest total estradiol quartile; Pinteraction = .04). Conclusions Women with lower pr-treatment endogenous estrogen levels were at greater risk of breast cancer during E+P therapy compared with those with higher levels. Further studies are warranted to confirm these findings. J Natl Cancer Inst;2013;105:1496–1503
Bernard Rosner - One of the best experts on this subject based on the ideXlab platform.
-
pre diagnostic Sex Hormone levels and survival among breast cancer patients
Breast Cancer Research and Treatment, 2019Co-Authors: Kevin H Kensler, Bernard Rosner, Heather A Eliassen, Susan E Hankinson, Myles Brown, Rulla M TamimiAbstract:Higher levels of circulating Sex steroid Hormones are associated with increased breast cancer risk, though their association with prognosis remains unclear. We evaluated the association between circulating Sex Hormone levels and breast cancer survival in two large cohorts. We evaluated this association among 2073 breast cancer cases from the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) cohorts. Women in this analysis provided a blood sample in 1989–1990 (NHS) or in 1996–1999 (NHSII) and were subsequently diagnosed with breast cancer. Levels of estradiol (postmenopausal women only), testosterone, dehydroepiandrosterone-sulfate (DHEAS), and Sex Hormone-binding globulin (SHBG) were measured in plasma. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for survival, adjusting for patient and tumor characteristics. A total of 639 deaths and 160 breast cancer deaths occurred over follow-up through 2015. Compared to women in the lowest quartile, postmenopausal women in the highest quartile of estradiol experienced a 1.43-fold overall mortality rate (HR 1.43, 95% CI 1.03–1.97, P-trend = 0.04) and a nonsignificantly higher breast cancer mortality rate (HR 1.50, 95% CI 0.75–2.98, P-trend = 0.12). Higher DHEAS levels were nonsignificantly associated with better overall survival (HRQ4vsQ1=0.79, 95% CI 0.57–1.10, P-trend = 0.05), though not with breast cancer survival. No associations were observed between testosterone or SHBG and survival. Pre-diagnostic postmenopausal circulating estradiol levels were modestly associated with worse survival among breast cancer patients. Further studies should evaluate whether circulating Hormone levels at diagnosis predict cancer prognosis or treatment response.
-
Sex Hormone levels and risk of primary open angle glaucoma in postmenopausal women
Menopause, 2018Co-Authors: Jae H Kang, Bernard Rosner, Janey L Wiggs, Louis R PasqualeAbstract:Objective We evaluated the relation of prediagnostic Sex Hormone levels in postmenopausal women with primary open-angle glaucoma (POAG) and intraocular pressure (IOP). Methods Among postmenopausal participants of the Nurses' Health Study, POAG cases (n = 189; diagnosed 1990-2008) and controls (n = 189) were matched on age, fasting status, and postmenopausal Hormone use at blood draw (1989-1990). Plasma concentrations of estrone sulfate, estradiol, testosterone, Sex Hormone binding globulin, and dehydroepiandrosterone sulfate were assessed. The primary outcome was POAG; in secondary analyses, among cases only, we evaluated maximum untreated IOP at diagnosis. Multivariable-adjusted logistic/multiple linear regression models were used to evaluate tertiles (Ts) of biomarker levels and the two outcomes, adjusting for various potential confounders. Results We observed no significant associations of estrone, estradiol, Sex Hormone binding globulin, or dehydroepiandrosterone sulfate with POAG risk or with maximum IOP at glaucoma diagnosis among cases. Suggestive significant associations were observed with highest testosterone and POAG risk (T3 vs T1 multivariable-adjusted odds ratio 1.84; 95% confidence interval 1.02, 3.33; P trend 0.10). Similarly, for maximum IOP at diagnosis among cases only (mean 8 years after blood draw), higher testosterone was significantly associated with higher IOP (multivariable-adjusted difference in IOP T3 vs T1 2.17 mm Hg; 95% confidence interval 0.34, 3.99; P trend 0.02). Conclusions Overall, plasma Sex Hormone levels in postmenopausal women were not associated with POAG risk; however, a trend of higher testosterone levels being associated with higher POAG risk and higher IOP at diagnosis was observed and needs confirmation.
-
the effects of caffeinated and decaffeinated coffee on Sex Hormone binding globulin and endogenous Sex Hormone levels a randomized controlled trial
Nutrition Journal, 2012Co-Authors: Nicole M Wedick, Christos S Mantzoros, Eric L Ding, Aoife M Brennan, Bernard Rosner, Eric B RimmAbstract:Background Findings from observational studies suggest that Sex Hormone-binding globulin (SHBG) and endogenous Sex Hormones may be mediators of the putative relation between coffee consumption and lower risk of type 2 diabetes. The objective of this study was to evaluate the effects of caffeinated and decaffeinated coffee on SHBG and Sex Hormone levels.
Susan E Hankinson - One of the best experts on this subject based on the ideXlab platform.
-
abstract p047 circulating testosterone and Sex Hormone binding globulin concentrations and risk of type 2 diabetes cardiovascular disease and all cause mortality in us women
Circulation, 2019Co-Authors: Tianyi Huang, Joann E Manson, Kathryn M Rexrode, Susan E Hankinson, Shelley S TworogerAbstract:Introduction: It remains unclear whether circulating testosterone and Sex Hormone-binding globulin (SHBG) are associated with cardiometabolic disease risk and mortality. Hypothesis: Higher SHBG and...
-
pre diagnostic Sex Hormone levels and survival among breast cancer patients
Breast Cancer Research and Treatment, 2019Co-Authors: Kevin H Kensler, Bernard Rosner, Heather A Eliassen, Susan E Hankinson, Myles Brown, Rulla M TamimiAbstract:Higher levels of circulating Sex steroid Hormones are associated with increased breast cancer risk, though their association with prognosis remains unclear. We evaluated the association between circulating Sex Hormone levels and breast cancer survival in two large cohorts. We evaluated this association among 2073 breast cancer cases from the Nurses’ Health Study (NHS) and Nurses’ Health Study II (NHSII) cohorts. Women in this analysis provided a blood sample in 1989–1990 (NHS) or in 1996–1999 (NHSII) and were subsequently diagnosed with breast cancer. Levels of estradiol (postmenopausal women only), testosterone, dehydroepiandrosterone-sulfate (DHEAS), and Sex Hormone-binding globulin (SHBG) were measured in plasma. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for survival, adjusting for patient and tumor characteristics. A total of 639 deaths and 160 breast cancer deaths occurred over follow-up through 2015. Compared to women in the lowest quartile, postmenopausal women in the highest quartile of estradiol experienced a 1.43-fold overall mortality rate (HR 1.43, 95% CI 1.03–1.97, P-trend = 0.04) and a nonsignificantly higher breast cancer mortality rate (HR 1.50, 95% CI 0.75–2.98, P-trend = 0.12). Higher DHEAS levels were nonsignificantly associated with better overall survival (HRQ4vsQ1=0.79, 95% CI 0.57–1.10, P-trend = 0.05), though not with breast cancer survival. No associations were observed between testosterone or SHBG and survival. Pre-diagnostic postmenopausal circulating estradiol levels were modestly associated with worse survival among breast cancer patients. Further studies should evaluate whether circulating Hormone levels at diagnosis predict cancer prognosis or treatment response.
-
relationship between caffeine intake and plasma Sex Hormone concentrations in premenopausal and postmenopausal women
Cancer, 2009Co-Authors: Joanne Kotsopoulos, Heather A Eliassen, Susan E Hankinson, Stacey A Missmer, Shelley S TworogerAbstract:BACKGROUND: Circulating estrogens and androgens are important factors in the development of various female cancers. Caffeine intake may decrease risk of breast and ovarian cancer, although the data are not entirely consistent. Whether or not caffeine affects cancer risk by altering Sex Hormone levels is currently unknown. METHODS: We examined the relationship of caffeine, coffee, decaffeinated coffee, and tea with plasma concentrations of estrogens, androgens, progesterone, prolactin, and Sex Hormone–binding globulin (SHBG) in 524 premenopausal and 713 postmenopausal women from the Nurses' Health Study (NHS) and NHSII. RESULTS: In premenopausal women, caffeine intake was inversely associated with luteal total and free estradiol, and positively associated with luteal progesterone levels (P-trend = .02, .01, .03, respectively). Coffee intake was significantly associated with lower luteal total and free estradiol levels, but not luteal progesterone levels (P-trend = .007, .004, .20, respectively). Among the postmenopausal women, there was a positive association between caffeine and coffee intake and SHBG levels (P-trend = .03 and .06, respectively). No significant associations were detected with the other Hormones. CONCLUSIONS: Data from this cross-sectional study suggest that caffeine may alter circulating levels of luteal estrogens and SHBG, representing possible mechanisms by which coffee or caffeine may be associated with pre- and postmenopausal malignancies, respectively. Future studies evaluating how caffeine-mediated alterations in Sex Hormones and binding protein levels affect the risk of female cancers are warranted. Cancer 2009. © 2009 American Cancer Society.
-
physical activity and inactivity in relation to Sex Hormone prolactin and insulin like growth factor concentrations in premenopausal women exercise and premenopausal Hormones
Cancer Causes & Control, 2007Co-Authors: Mitch Dowsett, Heather A Eliassen, Susan E Hankinson, Stacey A Missmer, Shelley S Tworoger, Robert L BarbieriAbstract:An association between physical activity and premenopausal breast cancer risk may be due, in part, to relationships with Sex Hormones or growth factors. Therefore, we assessed whether MET-h/week of total physical activity (moderate-to-vigorous intensity), walking, or vigorous physical activity, and h/week of standing or sitting were associated with plasma concentrations of several Hormones. We examined levels of estrogens, androgens, progesterone, prolactin, Sex Hormone binding globulin (SHBG), insulin-like growth factor-1 (IGF-1), IGF binding protein-3, and growth Hormone (GH) in 565 premenopausal women, ages 33-52 years, from the Nurses' Health Study II (NHSII). About 87% of women had both timed follicular and luteal samples; other women had one untimed sample. In general we observed few associations between Sex Hormone or IGF levels and measures of physical activity or inactivity. However, free testosterone was modestly inversely associated with total physical activity (p-trend = 0.02). Luteal estradiol, free estradiol, and estrone also were inversely associated with total physical activity (p-trend = 0.10, 0.04, 0.01, respectively); however, the trend was substantially attenuated when excluding women with anovulatory cycles or irregular cycles. These cross-sectional results suggest that physical activity and inactivity have limited associations with premenopausal Sex Hormone and growth factor levels, except possibly luteal estrogens.
Eric L Ding - One of the best experts on this subject based on the ideXlab platform.
-
the effects of caffeinated and decaffeinated coffee on Sex Hormone binding globulin and endogenous Sex Hormone levels a randomized controlled trial
Nutrition Journal, 2012Co-Authors: Nicole M Wedick, Christos S Mantzoros, Eric L Ding, Aoife M Brennan, Bernard Rosner, Eric B RimmAbstract:Background Findings from observational studies suggest that Sex Hormone-binding globulin (SHBG) and endogenous Sex Hormones may be mediators of the putative relation between coffee consumption and lower risk of type 2 diabetes. The objective of this study was to evaluate the effects of caffeinated and decaffeinated coffee on SHBG and Sex Hormone levels.
-
Sex Hormone binding globulin and risk of type 2 diabetes in women and men
The New England Journal of Medicine, 2009Co-Authors: Eric L Ding, Yiqing Song, Joann E Manson, David J Hunter, Nader Rifai, Julie E Buring, Michael J GazianoAbstract:Background Circulating Sex Hormone–binding globulin levels are inversely associated with insulin resistance, but whether these levels can predict the risk of developing type 2 diabetes is uncertain. Methods We performed a nested case–control study of postmenopausal women in the Women’s Health Study who were not using Hormone therapy (359 with newly diagnosed type 2 diabetes and 359 controls). Plasma levels of Sex Hormone–binding globulin were measured; two polymorphisms of the gene encoding Sex Hormone–binding globulin, SHBG, that were robustly associated with the protein levels were genotyped and applied in mendelian randomization analyses. We then conducted a replication study in an independent cohort of men from the Physicians’ Health Study II (170 with newly diagnosed type 2 diabetes and 170 controls). Results Among women, higher plasma levels of Sex Hormone–binding globulin were prospectively associated with a lower risk of type 2 diabetes: multivariable odds ratios were 1.00 for the first (lowest) quartile of plasma levels, 0.16 (95% confidence interval [CI], 0.08 to 0.33) for the second quartile, 0.04 (95% CI, 0.01 to 0.12) for the third quartile, and 0.09 (95% CI, 0.03 to 0.21) for the fourth (highest) quartile (P<0.001 for trend). These prospective associations were replicated among men (odds ratio for the highest quartile of plasma levels vs. the lowest quartile, 0.10; 95% CI, 0.03 to 0.36; P<0.001 for trend). As compared with homozygotes of the respective wild-type allele, carriers of a variant allele of the SHBG single-nucleotide polymorphism (SNP) rs6259 had 10% higher Sex Hormone–binding globulin levels (P = 0.005), and carriers of an rs6257 variant had 10% lower plasma levels (P = 0.004); variants of both SNPs were also associated with a risk of type 2 diabetes in directions corresponding to their associated Sex Hormone–binding globulin levels. In mendelian randomization analyses, the predicted odds ratio of type 2 diabetes per standard-deviation increase in the plasma level of Sex Hormone–binding globulin was 0.28 (95% CI, 0.13 to 0.58) among women and 0.29 (95% CI, 0.15 to 0.58) among men, a finding that suggests that Sex Hormone–binding globulin may have a causal role in the risk of type 2 diabetes. Conclusions Low circulating levels of Sex Hormone–binding globulin are a strong predictor of the risk of type 2 diabetes in women and men. The clinical usefulness of both SHBG genotypes and plasma levels in stratification and intervention for the risk of type 2 diabetes warrants further examination.
Eric B Rimm - One of the best experts on this subject based on the ideXlab platform.
-
the effects of caffeinated and decaffeinated coffee on Sex Hormone binding globulin and endogenous Sex Hormone levels a randomized controlled trial
Nutrition Journal, 2012Co-Authors: Nicole M Wedick, Christos S Mantzoros, Eric L Ding, Aoife M Brennan, Bernard Rosner, Eric B RimmAbstract:Background Findings from observational studies suggest that Sex Hormone-binding globulin (SHBG) and endogenous Sex Hormones may be mediators of the putative relation between coffee consumption and lower risk of type 2 diabetes. The objective of this study was to evaluate the effects of caffeinated and decaffeinated coffee on SHBG and Sex Hormone levels.
